GH Research PLC (NASDAQ:GHRS) Stock Has Consensus Target Price of $45.00

GH Research PLC (NASDAQ:GHRS) has been assigned a consensus recommendation of “Moderate Buy” from the twelve research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $45.00.

Several analysts have weighed in on the company. Wells Fargo & Company initiated coverage on GH Research in a research report on Monday, July 27th. They set an “overweight” rating and a $44.00 price objective on the stock. Wall Street Zen raised GH Research from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research note on Friday, July 17th. Zacks Research upgraded GH Research from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Finally, New Street Research set a $65.00 price target on GH Research in a research note on Monday, August 10th.

Institutional Trading of GH Research

Hedge funds and other institutional investors have recently modified their holdings of the business. Avoro Capital Advisors LLC purchased a new position in GH Research during the 4th quarter valued at about $22,860,000. Troluce Capital Advisors LLC grew its holdings in GH Research by 165.4% in the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock worth $13,926,000 after purchasing an additional 617,260 shares during the period. Braidwell LP purchased a new stake in GH Research in the second quarter worth about $5,571,000. CenterBook Partners LP grew its holdings in GH Research by 70.6% in the fourth quarter. CenterBook Partners LP now owns 283,441 shares of the company’s stock worth $3,600,000 after purchasing an additional 117,288 shares during the period. Finally, BIT Capital GmbH bought a new position in shares of GH Research during the fourth quarter valued at approximately $635,000. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Trading Down 3.4%

Shares of GH Research stock opened at $22.17 on Friday. GH Research has a 12-month low of $12.04 and a 12-month high of $31.44. The company has a market cap of $1.52 billion, a P/E ratio of -22.17 and a beta of 1.32. The company’s fifty day simple moving average is $27.63 and its two-hundred day simple moving average is $23.58.

GH Research (NASDAQ:GHRS) last announced its earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.06. Analysts predict that GH Research will post -1.2 EPS for the current fiscal year.

About GH Research

GH Research plc is a clinical-stage biopharmaceutical company focused on developing novel treatments for psychiatric and neurological disorders. The company’s research centers on mebufotenin, also known as 5-MeO-DMT, a psychedelic compound being evaluated through proprietary formulations and delivery methods designed to produce rapid-acting therapeutic effects.

GH Research’s lead investigational program, GH001, is an inhaled formulation of mebufotenin being studied for major depressive disorder, including treatment-resistant depression.